Chloramphenicol, an effective broad spectrum antibiotic, was introduced in 1948. Only after three years of extensive use did it become evident that this drug was capable of seriously depressing bone marrow activity in rare recipients. It was in response to the delay in recognizing the toxic potentialities of this drug that the American Medical Association established the Registry on Blood Dyscrasias, hoping, among other things, to recognize such effects early when they occurred for other new drugs. The Registry and its study group have since accumulated data on a large number of drugs, have issued periodic tabulations and resumes of cases submitted, and have authored commentaries on various associated problems.1-5 During this period, chloramphenicol has been implicated in more reports to the Registry than has any other single drug. It appeared that useful information could be obtained through a more thorough review of Registry reports.
Included in this study
Best WR. Chloramphenicol-Associated Blood DyscrasiasA Review of Cases Submitted to the American Medical Association Registry. JAMA. 1967;201(3):181–188. doi:10.1001/jama.1967.03130030051012